Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24535466 | 0.80 | CYP2D6 (0.43) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL22859842 | 0.80 | RECQL (0.32) | RECQL | |
| SCHEMBL21850104 | 0.76 | RECQL (0.31) | RECQL | |
| SCHEMBL22018635 | 0.76 | KMT2A (0.39) | HPGDLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL10245280 | 0.76 | MCL1 (0.41) | MMP1MMP8RECQLGAAKMT2A | |
| SCHEMBL10381056 | 0.76 | CYP2D6 (0.52) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL13373810 | 0.76 | CYP2D6 (0.52) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL22349837 | 0.75 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL10447542 | 0.74 | CYP2D6 (0.62) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL14805819 | 0.74 | EGLN1 (0.40) | HPGDRECQLUSP2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793881-B2 | Polyethylene glycol conjugate medicament, preparation method therefor and use thereof | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-10-24 | — | — | US | disclosed |
| EP-3889145-A1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20200316051-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316051-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP2D6 2908/4885CYP2C19 3103/4885MMP1 4259/4885 |
| US-11793881-B2 | Polyethylene glycol conjugate medicament, preparation method therefor and use thereof | SLC10A1, SLC10A2, NOTUM | CYP2D6 1166/4885CYP2C19 780/4885MMP1 2275/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP2D6 2085/4885CYP2C19 2398/4885MMP1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.